𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy

✍ Scribed by Chih-Lin Lin; Li-Ying Liao; Chaur-Shine Wang; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen; Jia-Horng Kao


Book ID
111237217
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
124 KB
Volume
24
Category
Article
ISSN
0106-9543

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Efficacy of lamivudine in patients with
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Precore/core promoter mutations and geno
✍ Chun-Jen Liu; Jia-Horng Kao; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Abstract The association of precore stop codon mutation (A1896), dinucleotide mutation (T1762/A1764) in the basic core promoter of hepatitis B virus (HBV) genome, and genotype of HBV with fulminant or subfulminant hepatitis remains controversial. We studied HBV genotypes as well as mutations in